Open Access

Astragaloside IV alleviates heart failure by regulating SUMO‑specific protease 1

  • Authors:
    • Juan Liu
    • Ya Li
    • Xiyun Bian
    • Na Xue
    • Jiancai Yu
    • Shipeng Dai
    • Xiaozhi Liu
  • View Affiliations

  • Published online on: July 28, 2021     https://doi.org/10.3892/etm.2021.10510
  • Article Number: 1076
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study investigated whether the protective effect and mechanism of astragaloside IV (AS‑IV) on heart failure (HF) involves small ubiquitin‑like modifier (SUMO)‑specific protease 1 (Senp1). Mouse HF was established by aortic constriction, inducing pressure overload. The model was confirmed by echocardiography 6 weeks after surgery. Mice were randomly divided into control, HF, HF+AS‑IV, and AS‑IV groups. Ventricular function was examined by echocardiography. Morphological changes of myocardial tissues were examined by H&E staining. The protein levels of the apoptosis‑related proteins, cleaved caspase‑3, caspase‑3, Bcl2, Bax, and SUMO‑Senp1 were determined by Western blotting. H2O2 in isolated mitochondria and cells was determined by Amplex Red. A reactive oxygen species (ROS) detection kit determined ROS levels in isolated mitochondria and HL‑1 cells. JC‑1 reagent measured mitochondrial membrane potential (ΔΨm). Apoptosis of HL‑1 cells was examined by terminal deoxynucleotidyl transferase dUTP nick end labeling. Compared with the control group, the heart weight and heart mass/body weight ratio increased in the HF group (P<0.05). Furthermore, the ejection fraction and left ventricular shortening fraction decreased (P<0.05), while the left ventricular end‑diastolic diameter (LVID;d) and end‑systolic diameter (LVID;s) increased (P<0.05). Finally, mitochondrial ROS and H2O2 increased (P<0.05), while the ΔΨm decreased (P<0.05). However, AS‑IV improved the cardiac function of HF mice, decreased the level of ROS and H2O2 in the myocardium, suppressed the decrease in ΔΨm, and decreased the apoptosis of myocardial cells (P<0.05). AS‑IV also decreased the Senp1‑overexpression. Furthermore, in HL‑1 cells, Senp1‑overexpression significantly inhibited the protective effects of AS‑IV. AS‑IV decreased oxidative stress in cardiomyocytes, decreased mitochondrial damage, inhibited ventricular remodeling, and ultimately improved cardiac function by inhibiting HF‑induced Senp1‑overexpression. This mechanism provides a novel theoretical basis and clinical treatment for HF.
View Figures
View References

Related Articles

Journal Cover

October-2021
Volume 22 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu J, Li Y, Bian X, Xue N, Yu J, Dai S and Liu X: Astragaloside IV alleviates heart failure by regulating SUMO‑specific protease 1. Exp Ther Med 22: 1076, 2021
APA
Liu, J., Li, Y., Bian, X., Xue, N., Yu, J., Dai, S., & Liu, X. (2021). Astragaloside IV alleviates heart failure by regulating SUMO‑specific protease 1. Experimental and Therapeutic Medicine, 22, 1076. https://doi.org/10.3892/etm.2021.10510
MLA
Liu, J., Li, Y., Bian, X., Xue, N., Yu, J., Dai, S., Liu, X."Astragaloside IV alleviates heart failure by regulating SUMO‑specific protease 1". Experimental and Therapeutic Medicine 22.4 (2021): 1076.
Chicago
Liu, J., Li, Y., Bian, X., Xue, N., Yu, J., Dai, S., Liu, X."Astragaloside IV alleviates heart failure by regulating SUMO‑specific protease 1". Experimental and Therapeutic Medicine 22, no. 4 (2021): 1076. https://doi.org/10.3892/etm.2021.10510